FoxHollow Believes Extracted Plaque Will Be Vital To PAD Drug Development
This article was originally published in The Gray Sheet
Executive Summary
FoxHollow Technologies plans to sell peripheral artery plaque extracted by itsSilverHawk excision system to pharmaceutical and biotech firms developing new therapies
You may also be interested in...
Pathway Medical Aims To Challenge FoxHollow In 2006 With Cardio-Path
Pathway Medical Technologies plans to commence an overseas, four-month clinical trial of its Cardio-Path plaque excision system for critical limb ischemia treatment this summer
Pathway Medical Aims To Challenge FoxHollow In 2006 With Cardio-Path
Pathway Medical Technologies plans to commence an overseas, four-month clinical trial of its Cardio-Path plaque excision system for critical limb ischemia treatment this summer
Foxhollow IPO Tabs $23 Mil. To Market Peripheral Plaque Excision System
Foxhollow Technologies may need to submit a new investigational device exemption to resume a trial of its SilverHawk plaque excision system for coronary use following a device redesign, the firm says